Jazz Pharmaceuticals (JAZZ) Other Operating Expenses (2010 - 2026)

Jazz Pharmaceuticals has reported Other Operating Expenses for 17 years, with the latest figure at $183.6 million in Q1 2026.

• For the quarter ending Q1 2026, Other Operating Expenses fell 29.11% year-over-year to $183.6 million; the trailing twelve-month figure through Mar 2026 stood at $2.0 billion (up 87.85% YoY), and the FY2025 full-year result was $2.1 billion, up 94.44% from the prior year.
• Other Operating Expenses for Q1 2026 stood at $183.6 million, down from $323.3 million in the prior quarter.
• The five-year high for Other Operating Expenses was $1.2 billion in Q2 2025, with the low at $183.6 million in Q1 2026.
• Average Other Operating Expenses over 5 years is $361.9 million, with a median of $279.4 million recorded in 2023.
• Year-over-year, Other Operating Expenses sank 59.28% in 2023 and surged 346.48% in 2025.
• Tracing JAZZ's Other Operating Expenses over 5 years: stood at $679.8 million in 2022, then slumped by 59.28% to $276.8 million in 2023, then gained by 3.91% to $287.6 million in 2024, then advanced by 12.4% to $323.3 million in 2025, then plunged by 43.21% to $183.6 million in 2026.
• The last three Other Operating Expenses figures came in at $183.6 million (Q1 2026), $323.3 million (Q4 2025), and $339.7 million (Q3 2025), per Business Quant data.

Peer Comparison